Danville, Penn.-based Geisinger is teaming with an Israeli artificial intelligence vendor to better diagnose and treat patients with high-burden diseases.
Under the multi-year partnership, Geisinger’s Steele Institute for Health Innovation is working with Israel’s Medial EarlySign to develop and deploy a suite of machine learning-based solutions.
“Leveraging Geisinger’s performance as a national leader in healthcare and its culture of innovation with EarlySign’s expertise in machine learning and data analytics will enable us to identify, evaluate and intervene with high-risk patients earlier,” says Karen Murphy, executive vice president and chief innovation officer at Geisinger. “This collaboration will help us potentially save lives and improve the care we provide patients by deepening our experience with AI and identifying new ways to integrate it into daily clinical care.”
Also See: Health IT tool at Mass General aids care for patients with chronic disease
Initially, the two organizations will focus on lower GI disorders. EarlySign’s LGI-Flag, which analyzes clinical data to identify patients who will benefit from further evaluation, has been leveraged over the last few years by healthcare systems worldwide for lower GI disorders associated with chronic occult bleeding.
“EarlySign’s technology and the LGI-Flag solution will potentially assist our teams to more quickly identify significant lower GI disorders and intervene earlier than we historically have been able to,” says Keith A. Boell, DO, associate chief quality officer at Geisinger. “We look forward to advancing our use of this technology while leveraging our experience to help more patients benefit from these life-changing medical advances.”
“We are delighted to be partnering with Geisinger, which shares our commitment to innovation and to offering the most effective care for challenging health issues,” says Ori Geva, cofounder and CEO of Medial EarlySign. “This is the first step of our ultimate goal: enabling healthcare systems to identify and connect with those high-risk patients and engage with them early enough via interventions that may prevent or delay disease progression.”
For reprint and licensing requests for this article, click here.